Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S

Reuters

06-06

Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S

DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. $(AYTU)$ announced that it has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, a novel antidepressant, is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder (MDD) in adults. The transaction is financed by long-term, healthcare-focused institutional investors, including Nantahala Capital Management and Stonepine Capital Management. Aytu is preparing to launch EXXUA in the U.S. by the fourth quarter of 2025, aiming to make it a central element of their commercial strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036228) on June 06, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2541852460"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541852460\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2541852460?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-06 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541852460","market":"nz","top_or_hot":-1,"title":"Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        DENVER, CO / ACCESS Newswire / June 6, 2025 / <a href=\"https://laohu8.com/S/AYTUZ\">Aytu BioPharma, Inc.</a> <a href=\"https://laohu8.com/S/AYTU\">$(AYTU)$</a> announced that it has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, a novel antidepressant, is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder (MDD) in adults. The transaction is financed by long-term, healthcare-focused institutional investors, including Nantahala Capital Management and Stonepine Capital Management. Aytu is preparing to launch EXXUA in the U.S. by the fourth quarter of 2025, aiming to make it a central element of their commercial strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036228) on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-06 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        DENVER, CO / ACCESS Newswire / June 6, 2025 / <a href=\"https://laohu8.com/S/AYTUZ\">Aytu BioPharma, Inc.</a> <a href=\"https://laohu8.com/S/AYTU\">$(AYTU)$</a> announced that it has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, a novel antidepressant, is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder (MDD) in adults. The transaction is financed by long-term, healthcare-focused institutional investors, including Nantahala Capital Management and Stonepine Capital Management. Aytu is preparing to launch EXXUA in the U.S. by the fourth quarter of 2025, aiming to make it a central element of their commercial strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036228) on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL5Lzyrd:1","article_id":"2541852460","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541852460","pubTimestamp":1749211242,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc.  announced that it has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA  extended-release tablets in the United States. EXXUA, a novel antidepressant, is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder  in adults. The transaction is financed by long-term, healthcare-focused institutional investors, including Nantahala Capital Management and Stonepine Capital Management. Aytu is preparing to launch EXXUA in the U.S. by the fourth quarter of 2025, aiming to make it a central element of their commercial strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Aytu BioPharma Inc.获得EXXUA在美国商业化用于MDD治疗的独家协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AYTU":0.9},"content_text":"Aytu BioPharma Inc. Secures Exclusive Agreement to Commercialize EXXUA for MDD Treatment in the U.S\n    \n\n        DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. $(AYTU)$ announced that it has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, a novel antidepressant, is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for treating major depressive disorder (MDD) in adults. The transaction is financed by long-term, healthcare-focused institutional investors, including Nantahala Capital Management and Stonepine Capital Management. Aytu is preparing to launch EXXUA in the U.S. by the fourth quarter of 2025, aiming to make it a central element of their commercial strategy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1036228) on June 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}